Aspen is authorized to sell Lilly’s Mounjaro for weight loss in South Africa
Aspen Pharmacare (APNJ.J), a new tab manufacturer in South Africa, announced on Monday that it had obtained regulatory approval to sell Eli Lilly’s (LLY.N) popular diabetic and obesity medication, Mounjaro, for the country’s chronic weight management.
The clearance comes after Aspen’s previous approval and introduction of the medication, which is chemically known as tirzepatide, as a Type 2 diabetes treatment in South Africa in December.
Mounjaro, a simple KwikPen injector device, will be introduced in South Africa by Aspen, a Lilly sales representative, for weight management.
The business has been placing bets on Mounjaro’s impending introduction to take on Novo Nordisk’s (NOVOb.CO), a new tablet rival medicine that the Danish pharmaceutical company introduced in South Africa in August, eight months after Eli Lilly.
Given the rising demand for obesity treatments worldwide, the South African Health Products Regulatory Authority’s approval puts Aspen in a strong position to capitalize on the weight-loss medication industry, which is predicted to reach at least $100 billion by the end of the decade.
